Floatz logo

Eplontersen

Transthyretin-mediated Amyloidosis

AstraZenecaPhase 1Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Transthyretin-mediated Amyloidosis cohort.

Asset / SponsorPhaseRating
Aln-Ttrsc04
Alnylam Pharmaceuticals
Phase 1CC

Same molecule, other indications

Eplontersen is also rated in:

Transthyretin Amyloid CardiomyopathyDormant
B
Indicative ·
60 / 100
View asset →
Transthyretin Amyloid Cardiomyopathy (ATTR-CM)Dormant
CCC
Indicative ·
53 / 100
View asset →
Healthy VolunteersDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →